Inovio Expands Enrollment in Ebola Vaccine Phase I Study

Late last week, Inovio Pharmaceuticals, Inc.INO announced that it is expanding the enrollment in a phase I study evaluating its Ebola DNA vaccine, INO 4212. The company is enrolling 125 patients in the second stage of a phase I